Overview and Scope
The oral expectorant market consists of sales of products such as combination expectorants and cough suppressants, natural and homeopathic expectorants, expectorant lozenges and troches, multisymptomatic cold and flu medications containing expectorants, and pediatric expectorants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The oral expectorant market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.18 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to increasing prevalence of respiratory illnesses, rising demand for over-the-counter medications, growing geriatric population, rising pollution levels, increasing awareness about respiratory health, and expansion of pharmaceutical distribution channels.
The oral expectorant market size is expected to see steady growth in the next few years. It will grow to $5.03 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing investments in research and development, increasing investments in research and development, growing demand for natural and herbal expectorants, regulatory approvals for new products, rising healthcare expenditure, and adoption of innovative marketing strategies. Major trends in the forecast period include integration of digital health platforms for medication management, shift towards sustainable packaging and manufacturing practices, development of combination therapies targeting multiple respiratory symptoms, personalized medicine approaches based on genetic profiling, emphasis on patient-centric care and telemedicine services, and utilization of artificial intelligence and big data analytics for drug discovery and development.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report
Segmentation & Regional Insights
The oral expectorant market covered in this report is segmented –
1) By Drug Type: Secretion Enhancer, Mucolytics
2) By Dosage Form: Oral Solids, Oral Liquids, Inhalants
3) By Medication: Prescription drugs, Over The Counter Drugs
4) By Distribution Channel: Hospital Pharmacy, Retail Store And Drug Store, Online Pharmacies
North America was the largest region in the oral expectorant market in 2023. The regions covered in the oral expectorant market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16496&type=smp
Major Driver Impacting Market Growth
The rise in respiratory illnesses is expected to propel the growth of the oral expectorant market going forward. Respiratory illnesses refer to diseases and conditions that affect the respiratory system, including the lungs, airways, and other structures involved in breathing. The number of respiratory illness cases occurs due to air pollution, smoking, respiratory infections, and a rise in chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). Oral expectorants alleviate symptoms and improve respiratory health for individuals with respiratory illnesses. They also help in clearing mucus, ease breathing, and support overall recovery and well-being. For instance, in May 2024, according to the data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Furthermore, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of respiratory syncytial virus (RSV) that causes respiratory illness were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020–21. Therefore, an increasing number of corporate travelers is driving the oral expectorant market.
Key Industry Players
Major companies operating in the oral expectorant market are Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline (GSK) plc, Merck KGaA, Reckitt Benckiser Group PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca plc , Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories, Hikma Pharmaceuticals PLC, C.H. Boehringer Sohn AG And Co. KG , Lupin Pharmaceuticals, Taro Pharmaceutical Industries Ltd., Perrigo Company plc, Biocon India Private Limited, Cadila Healthcare Ltd., Wockhardt Ltd, Genexa Inc.
The oral expectorant market report table of contents includes:
- Executive Summary
- Oral Expectorant Market Characteristics
- Oral Expectorant Market Trends And Strategies
- Oral Expectorant Market – Macro Economic Scenario
- Global Oral Expectorant Market Size and Growth
………….
- Global Oral Expectorant Market Competitive Dashboard
- Key Mergers And Acquisitions In The Oral Expectorant Market
- Oral Expectorant Market Future Outlook and Potential Analysis
- Appendix
List Of Tables:
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Oral Expectorant Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Oral Expectorant Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Oral Expectorant Market, Segmentation By Medication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
………..
Table 75: Bayer AG Financial Performance
Table 76: Sanofi S.A. Financial Performance
Table 77: Bristol-Myers Squibb Company Financial Performance
Table 78: Abbott Laboratories Ltd Financial Performance
Table 79: Novartis AG Financial Performance
Explore the trending research reports from TBRC:
https://goodprnews.com/visual-positioning-system-market-growth/
https://topprnews.com/warmer-display-cases-market-share/
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
